The National Institute for Health and Care Excellence (NICE) recommended Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), for NHS use in treating type 2 diabetes.
This treatment could reduce the number of annual injections for patients by as much as 85%.
The recommendation particularly benefits patients who require assistance with their insulin administration.
National coverage in England remains contingent upon marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA).
The European Medicines Agency’s committee previously issued a positive opinion on the drug in June 2026.
NICE based its decision on Phase III data demonstrating that Onswik’s blood glucose control is comparable to existing daily long-acting insulins.